Bruno D. Chapsal*, Jennifer R. Kimbrough, Stephanie M. Bester, Alex Bergstrom, Donald S. Backos, Bismarck Campos, Matthew G. McDonald, Rebecca Abrahamsen, Andrew C. Allen, Patrick M. Doerner Barbour, Tanna Bettendorf, Mark L. Boys, Karin Brown, Mark J. Chicarelli, Adam W. Cook, Amy L. Crooks, Cole L. Cruz, Joshua R. Dahlke, Alida Eide, Jay B. Fell, Jennifer L. Fulton, Matthew Gargus, John J. Gaudino, Anna L. Guarnieri, Erik P. Hansen, Melissa C. Holt, Dean R. Kahn, Ellen R. Laird, Paul D. Larsen, Rebecca Linwood, Matthew C. Martinson, Joseph McCown, Macedonio J. Mejia, David A. Moreno, Tung-Chung Mou, Brad Newhouse, Jacob M. O’Leary, Martha E. Rodriguez, Anurag Singh, Lenka Sinik, Keith A. Strand, Eric E. Touney, Lance A. Wollenberg, Jim Wong, Yeyun Zhou, John P. Fischer and Shelley Allen,
{"title":"Design of Potent Menin–KMT2A Interaction Inhibitors with Improved In Vitro ADME Properties and Reduced hERG Affinity","authors":"Bruno D. Chapsal*, Jennifer R. Kimbrough, Stephanie M. Bester, Alex Bergstrom, Donald S. Backos, Bismarck Campos, Matthew G. McDonald, Rebecca Abrahamsen, Andrew C. Allen, Patrick M. Doerner Barbour, Tanna Bettendorf, Mark L. Boys, Karin Brown, Mark J. Chicarelli, Adam W. Cook, Amy L. Crooks, Cole L. Cruz, Joshua R. Dahlke, Alida Eide, Jay B. Fell, Jennifer L. Fulton, Matthew Gargus, John J. Gaudino, Anna L. Guarnieri, Erik P. Hansen, Melissa C. Holt, Dean R. Kahn, Ellen R. Laird, Paul D. Larsen, Rebecca Linwood, Matthew C. Martinson, Joseph McCown, Macedonio J. Mejia, David A. Moreno, Tung-Chung Mou, Brad Newhouse, Jacob M. O’Leary, Martha E. Rodriguez, Anurag Singh, Lenka Sinik, Keith A. Strand, Eric E. Touney, Lance A. Wollenberg, Jim Wong, Yeyun Zhou, John P. Fischer and Shelley Allen, ","doi":"10.1021/acsmedchemlett.4c0031110.1021/acsmedchemlett.4c00311","DOIUrl":null,"url":null,"abstract":"<p >Inhibitors of the interaction of menin (MEN1) with lysine methyltransferase 2A (KMT2A) have emerged as novel therapeutic options in the treatment of genetically defined acute leukemias. Herein, we describe the structure-based design, synthesis, and biological evaluation of novel inhibitors of the menin–KMT2A interaction. Our structure–activity relationship campaign focused on achieving high antiproliferative cellular activity while mitigating risks associated with CYP3A4-dependent metabolism and hERG inhibition, which were characterized in some early clinical candidates. Our efforts resulted in the discovery of a triazine-based compound series that inhibited MV4-11 leukemia cell line proliferation with IC<sub>50</sub> as low as 13 nM, and selected compounds demonstrated improved <i>in vitro</i> ADME properties, de-risked CYP3A4 dependency, and lower hERG inhibition.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 2","pages":"224–233 224–233"},"PeriodicalIF":3.5000,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsmedchemlett.4c00311","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Inhibitors of the interaction of menin (MEN1) with lysine methyltransferase 2A (KMT2A) have emerged as novel therapeutic options in the treatment of genetically defined acute leukemias. Herein, we describe the structure-based design, synthesis, and biological evaluation of novel inhibitors of the menin–KMT2A interaction. Our structure–activity relationship campaign focused on achieving high antiproliferative cellular activity while mitigating risks associated with CYP3A4-dependent metabolism and hERG inhibition, which were characterized in some early clinical candidates. Our efforts resulted in the discovery of a triazine-based compound series that inhibited MV4-11 leukemia cell line proliferation with IC50 as low as 13 nM, and selected compounds demonstrated improved in vitro ADME properties, de-risked CYP3A4 dependency, and lower hERG inhibition.
期刊介绍：
ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to:
Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics)
Biological characterization of new molecular entities in the context of drug discovery
Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc.
Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry
Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources
Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response
Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic
Mechanistic drug metabolism and regulation of metabolic enzyme gene expression
Chemistry patents relevant to the medicinal chemistry field.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
